935759-86-7

Upstream product

• 31197-30-5 1-(3-bromophenyl)piperazine 
• 327030-39-7 1,1-dimethylethyl 4-(3-bromophenyl)piperazine-1-carboxylate 
• 807624-20-0 1,1-dimethylethyl 4-(3-cyanophenyl)piperazine-1-carboxylate 
• 889948-55-4 1,1-dimethylethyl 4-[3-(aminomethyl)phenyl]piperazine-1-carboxylate 
• 935760-79-5 1,1-dimethylethyl 4-[3-({[(4-oxo-3,4-dihydroquinazolin-2-yl)carbonyl]amino}methyl)phenyl]piperazine-1-carboxylate 
• 5427-26-9 5-hydantoinacetic acid 

Relevant academic research and scientific papers

Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors

Matrix metalloproteinase-13 (MMP-13), a member of the collagenase family of enzymes, has been implicated to play a key role in the pathology of osteoarthritis. Recently, we have reported the discovery of a series of quinazoline-2-carboxamide based non-zin

HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF

The present invention provides a novel amide compound represented by the following formula, which has a matrix metalloproteinase inhibitory activity and is useful as a pharmaceutical agent. wherein each symbol is as defined in the specification.